Clinical utility of circulating tumor cells: A role for monitoring response to therapy and drug development

Biomarkers in Medicine

Volumn 2, Issue 2, 2008, Pages 137-145

  Urtishak, Sandra ^a   Alpaugh, R Katherine ^a   Weiner, Louis M ^b   Swaby, Ramona F ^a  

^a FOX CHASE CANCER CENTER   (United States)

^b GEORGETOWN UNIVERSITY   (United States)

Author keywords

Biomarkers; CEC; Circulating endothelial cells; Circulating tumor cells; CTC; Developmental therapeutics; Experimental therapeutics; Tumor markers

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CARCINOEMBRYONIC ANTIGEN; COMPLEMENTARY DNA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; MESSENGER RNA; PROTEIN KINASE B; TUMOR MARKER;

ANALYTICAL EQUIPMENT; AUTOANALYZER; BREAST CANCER; CANCER PATIENT; CANCER STAGING; CARCINOGENESIS; CELL ISOLATION; CELL POPULATION; CLINICAL ASSESSMENT TOOL; CLINICAL TRIAL; COLORECTAL CANCER; DIAGNOSTIC ACCURACY; DNA MICROARRAY; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG MONITORING; DRUG RESEARCH; DRUG TARGETING; ENDOTHELIUM CELL; FLOW CYTOMETRY; GENOTYPE; HUMAN; IMMUNOMAGNETIC SEPARATION; LOW DRUG DOSE; MELANOMA; METASTASIS; OVERALL SURVIVAL; PANCREAS CANCER; PHENOTYPE; PROGNOSIS; PROSTATE CANCER; RECTUM CANCER; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SENSITIVITY AND SPECIFICITY; SOLID TUMOR; STOMACH CANCER; TUMOR CELL;

EID: 44449132629     PISSN: 17520363     EISSN: None     Source Type: Journal    
DOI: 10.2217/17520363.2.2.137     Document Type: Review

References (44)

1. Ashworth T: A case of cancer in which cells similar to those in the tumors were see in the blood after death. Aust. Med. J. 14, 146-149 (1869).
2. Rao C, Bui T, Yao Y et al.: Automated system to enumerate circulating tumor cells in blood. In: Proceedings af the 95th Annual Meeting of the American Association f or Cancer Research. Orlando, FL, USA, 27-31 March 2004 (Abstract 3294).
3. Long L, Jonasson O, Roberts S, McGrath R, McGrew E, Cole WH: Cancer cells in blood. Results of a simplified isolation technique. Arch. Surg. 80, 910-919 (1960).
4. Roberts S, Watne A, McGrath R, McGrew E, Cole WH: Technique and results of isolation of cancer cells from the circulating blood. AMA Arch. Surg. 76(3), 334-346 (1958).
5. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC: Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N. Engl. J. Med. 351(8), 781-791 (2004).
6. Cristofanilli M, Hayes DF, Budd GT, Ellis MJ, Stopeck A, Reuben JM: Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J. Clin. Oncal. 23(7), 1420-1430 (2005).
7. Wiegelt B, Bosma AJ, Hart AA, Rodenhuis S, vant Veer LJ: Marker genes for circulating tumour cells predict survival in metastasized breast cancer patients. Br. J. Cancer 88(7), 1091-1094 (2003).
8. Stathopoulou A, Vlachonikolis I, Mavroudis D, Perraki M, Kouroussis C, Apostolaki S: Molecular detection of cytokeratin-19-positive cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic significance. J. Clin. Oncol. 20(16), 3404-3412 (2002).
9. Moreno JG, Miller MC, Gross S, Allard WJ, Gomella LG, Terstappen LW: Circulating tumor cells predict survival in patients with metastatic prostate cancer. Urology 65(4), 713-718 (2005).
10. Ulmer A, Schmidt-Kittler O, Fischer J, Ellwanter U, Rassner G, Riethmuller G: Immunomegnetic enrichment, genomic characterization, and prognostic impact of circulating melanoma cells. Clin. Cancer Res. 10(2), 531-537 (2004).
11. Mocellin S, Del Fiore P, Guarnieri L et al.: Molecular detection of circulating tumor cells in an independent prognostic factor in patients with high-risk cutaneous melanoma. Int. J. Cancer 111(5), 741-745 (2004).
12. Mocellin S, Keilholz U, Rossi CR, Nitti D: Circulating tumor cells: the 'leukemic phase' of solid cancers. Trends Mol. Med. 12(3), 130-139 (2006).
13. Bai VU, Kaseb A, Tejwani S et al.: Identification of prostate cancer mRNA markers by averaged differential expression and their detection in biopsies, blood, and urine. Proc. Natl Acad. Sci. USA 104(7), 2343-2348 (2007).
14. Ring AE, Zabaglo, L, Ormerod MG, Smith IE, Dowsett M: Detection of circulating epithelial cells in the blood of patients with breast cancer: comparison of three techniques. Br. J. Cancer92, 906-912 (2005).
15. Zippelius A, Kufer P, Honold G et al.: Limitations of reverse-transcriptase polymerase reaction analysis for detection of micrometastatic epithelial cancer calls in bone marrow. J. Clin. Oncol. 15, 2701-2708 (1997).
16. Becker S, Becker-Pergola G, Fehm T, Wallwiener D, Solomayer EF: Time is an Important factor when processing samples for the detection of disseminated tumor cell in blood/bone marrow by reverse-transcription-PCR. Clin. Chemistry 50(4), 785-786 (2004).
17. Gross HJ, Verwer B, Houck D, Hoffman RA, Recktenwalkd D: Model study detecting breast cancer cells in peripheral blood mononuclear cells at frequencies as low as 107. Proc. Natl Acad. Sci. USA 92(2), 537-541 (1995).
18. Martin KJ, Graner E, Li Y et al.: High-sensitivity array analysis of gene expression for the early detection of disseminated breast tumor cells in peripheral blood. Proc. Natl Acad. Sci. USA 98(5), 2646-2651 (2001).
19. Racila E, Euhus D, Weiss AJ et al.: Detection and characterization of carcinoma cells in the blood. Proc. Natl Acad. Sci. USA 95(8), 4589-4594 (1998).
20. Patel H, Le Marer N, Wharton RQ et al.: Clearance of circulating tumor cells after excision of primary colorectal cancer. Ann. Surg. 235(2), 226-231 (2002).
21. Allen-Mersh TG, McCullough TK, Patel H, Wharton RQ, Glover C, Jonas SK: Role of circulating tumour cells in predicting recurrence after excision of primary colorectal carcinoma. Br. J. Surg. 94, 96-105 (2007).
22. Bessa X, Elizalde JI, Boix L et al.: Lack of prognostic influence of circulating tumor cells in peripheral blood of patients with colorectal cancer. Gastroenterology 120(5), 1082-1092 (2001).
23. Ikeguchi M, Kalbara N: Detection of circulating cancer cells after a gastrectomy for gastric cancer. Surg. Today 35(6), 436-441 (2005).
24. Miyazono F. Natsugoe S, Takao S et al.: Surgical maneuvers enhance molecular detection of circulating tumor cells during gastric cancer surgery. Ann. Surg. 233(2), 189-194 (2001).
25. Nishida S, Kitamura K, Ichikawa D, Koike H, Tani N, Yamagishi H: Molecular detection of disseminated cancer cells in the peripheral blood of patients with gastric cancer. Anticancer Res. 20(3B), 2155-2159 (2000).
26. Uchikura K, Takao S, Nakajo A et al.: Intraoperative molecular detection of circulating tumor cells by reverse transcription polymerase Cain reaction in patients with billary-pancreatic cancer is associated with hematogenous metastasis. Ann. Surg. Oncol. 9(4), 364-370 (2002).
27. Mocellin S, Hoon D, Ambrosi A, Nitti D, Rossi CR: The prognostic value of circulating tumor cells in patients with melanoma: a systematic review and meta-analysis. Clin. Cancer Res. 12(15). 4605-4613 (2006).
28. Budd GT, Cristofanilli M, Ellis MJ et al.: Circulating tumor cells versus imaging-predicting overall survival in metastatic breast cancer. Clin. Cancer Res. 12(21), 6403-6409 (2006).
29. Pachmann K, Camara O, Kavallaris A, Schneider U, Schunemann S, Hoffken K: Quantification of the response of circulating epithelial cells to neoadjuvant treatment for breast cancer: a new too for therapy monitoring. Breast Cancer Res. 7(6), R975-R979 (2005).
30. Xendidis N, Mavroudis D, Apostolaki S et al.: Effect of adjuvant treatment on the circulating CK-19 mRNA-positive tumor cells in patients with early stage breast cancer. J. Clin. Oncol. 24, 18S (2006) (Abstract 20012).
31. Palmieri G, Satriano, SM, Budnoni M et al.: Serial detection of circulating tumour cells by reverse transcriptase-polymerase chain reaction assays is a marker for poor outcome in patients with malignant melanoma. BMC Cancer 6, 266 (2006).
32. Cohen SJ, Punt CJ, Iannotti N et al.: Monitoring patients with metastatic colorectal cancer (mCRC) using circulating tumor cells (CTC). Presented at: ASCO 2007 Gastrointestinal Cancers Symposium. Orlanso, FL, USA, 19-21 January 2007 (Abstract 342).
33. Cohen SJ, Alpaugh RK, Gross S et al.: Isolation and characterization of circulating tumor cells in patients with metastatic colorectal cancer. Clin. Colorectal Cancer 6(2), 125-132 (2006).
34. O'Hara SM, Moreno JG, Zweitzig DR, Gross S, Gomella LG, Terstappen LW: Multigene reverse transcription-PCR profiling of circulating tumor cells in hormone-refractory prostate cancer. Clin. Chem. 50(5), 826-835 (2004).
35. Magbanua MM, Lang JE, Scott J et al.: Gene expression profiling of circulating tumor cells from breast cancer patients. J. Clin. Oncol. 24, 18S (2006) (Abstract 10769).
36. Wulfing P, Borchard J, Buerger H et al.: HER2-positive circulating tumor cells indicate poor clinical outcome in stage I to III breast cancer patients. Clin. Cancer Res. 12(6), 1715-1720 (2006).
37. Hayes DF, Walker TM, Singh B et al.: Monitoring expression of HER-2 on circulating epithelial cells in patients with advanced breast cancer. Int. J. Oncol. 21(5), 1111-1117 (2002).
38. Meng S, Tripathy D, Shete S et al.: HER-2 gene amplification can be acquired as breast cancer progresses. Proc. Natl Acad Sci. USA 101(25), 9393-9398 (2004).
39. Pachman K, Camara O, Lobodasch K et al.: Circulating tumor cells: Tools for monitoring and targets for therapy. J. Clin. Oncol. 24, 18S (2006) (Abstract 617).
40. Beerepoot LV, Mehra N, Vermaat JS, Zonnenberg BA, Gebbink MF, Voest EE: Increased levels of viable circulating endothelial cells are an indicator of progressive disease in cancer patients. Ann. Oncol. 15(1), 139-145 (2004).
41. Smirnov DA, Foulk BW. Dovle GV, Connelly MC, Terstappen LW. O'Hara SM: Global gene expression profiling of circulating endothelial cells in patients with metastatic carcinomas. Cancer Res. 66(6), 2918-2922 (2006).
42. Willett CG, Boucher Y, Duda DG et al.: Surrogate markers for antiangiogenic therapy and close-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a Phase I trial in rectal cancer patients. J. Clin. Oncol. 23(31), 8136-8139 (2005).
43. Beaudry P, Force J, Naumov GN et al.: Differential effects of vascular endothelial growth factor receptor-2 inhibitor ZD6474 on circulating endothelial progenitors and mature circulating endothelial cells: implications for use as a surrogate marker of antiangtogenic activity. Clin Cancer Res. 11(9), 3514-3522 (2005).
44. Rugo HS, Dickler MN, Scott JH et al.: Change in circulating endothelial cells (CEC) and tumor cells(CTC) in patients (pts) receiving bevacizumab and Erlotinib for metastatic breast cancer (MBC) predicts stable disease in first evaluation. J. Clin. Oncol. 23, 16S (2005) (Abstract 525).